Predictmedix AI Announces Private Placement

Rhea-AI Summary

Predictmedix AI (CSE: PMED) (OTC: PMEDF) has announced a non-brokered private placement offering of up to 50,000,000 units at C$0.02 per unit, aiming to raise up to C$1,000,000. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of one common share at C$0.05 within 24 months of closing.

The company has begun receiving commitments for the placement, according to COO Dr. Rahul Kushwah. The proceeds will be allocated to general working capital and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors. All securities issued will have a four-month and one-day statutory hold period.

Positive

• Securing up to C$1,000,000 in additional funding
• Strategic expansion into U.S. markets

Negative

• Significant shareholder dilution through 50 million new units
• Low unit pricing at C$0.02 indicates potential undervaluation
• Additional dilution risk through warrants at C$0.05

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) (the “Company” or “Predictmedix”), a leading provider of rapid health screening announces a proposed non brokered private placement. The Company intends to issue (the “Offering”) of up to 50,000,000 units (each, a “Unit”) at a price of C$0.02 per Unit, for aggregate gross proceeds to the Company of up to C$1,000,000. Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company at a price of C$0.05 for a period of 24 months following the closing date of the Offering.

“We are pleased to announce that the company has begun receiving commitments towards the placement,” said Dr. Rahul Kushwah, COO of Predictmedix.

The net proceeds will be used for general working capital needs while also for unlocking market opportunities in the U.S., for the AI-powered health management solutions across enterprise and government sectors. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.

To receive company news, please sign up for alerts at the bottom of the page link below:
https://predictmedix.com/press-releases/

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.”

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211973209/en/

Dr. Rahul Kushwah, COO

rahul@predictmedix.com

(647) 889 6916

Source: Predictmedix AI Inc.

FAQ

What are the terms of Predictmedix AI's (PMEDF) private placement offering?

The offering consists of up to 50,000,000 units at C$0.02 per unit, with each unit including one common share and one warrant exercisable at C$0.05 for 24 months.

How much capital is Predictmedix AI (PMEDF) aiming to raise through the private placement?

Predictmedix AI aims to raise up to C$1,000,000 through this private placement offering.

What is the lock-up period for securities issued in PMEDF's private placement?

All securities issued in the private placement will have a statutory hold period of four months and one day from the date of issuance.

How will Predictmedix AI (PMEDF) use the proceeds from the private placement?

The proceeds will be used for general working capital needs and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors.